Drug profile · INN
molnupiravir
LAGEVRIO
molnupiravir (LAGEVRIO) is a rna disrupting agent. Associated with Merck KGaA, Darmstadt, Germany.
EMA: application withdrawn TGA: approved PMDA: approved Antiinfectives for systemic use (J05) J05A
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — molnupiravir
- Class
- Antiinfectives for systemic use (J05)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
molnupiravir (LAGEVRIO) is a rna disrupting agent. Associated with Merck KGaA, Darmstadt, Germany.
Key facts
INN molnupiravir
Brand LAGEVRIO
Mechanism RNA disrupting agent
Target RNA
Therapeutic class Antiinfectives for systemic use (J05)
ATC code J05A
Originator Merck KGaA, Darmstadt, Germany
Mechanism of action
RNA disrupting agent
Primary target: RNA
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is molnupiravir?
molnupiravir (LAGEVRIO) is a rna disrupting agent. Associated with Merck KGaA, Darmstadt, Germany.
What is the brand name for molnupiravir?
LAGEVRIO is a marketed brand name for molnupiravir. Check FDA Drugs@FDA for the current US label holder and prescribing information.